<DOC>
	<DOCNO>NCT01490112</DOCNO>
	<brief_summary>This study conduct Asia . The aim study observe safety efficacy insulin aspart ( NovoRapid® ) administer via vial three different device .</brief_summary>
	<brief_title>Surveillance Study NovoRapid® New Drug Re-examination</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Subjects diabetes mellitus ( type 1 , type 2 , gestational ) prescribe insulin aspart ( NovoRapid® )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>